disitamab vedotin + toripalimab + epirubicin + cyclophosphamide

This drug is a **combination regimen** of four agents: - **disitamab vedotin**: an antibody-drug conjugate that targets HER2 (ERBB2), delivering a cytotoxic agent to HER2-expressing cancer cells - **toripalimab**: a monoclonal antibody and immune checkpoint inhibitor targeting programmed death-1 (PD-1), enhancing anti-tumor immune response - **epirubicin**: an anthracycline cytotoxic chemotherapy agent that intercalates DNA and inhibits topoisomerase II, leading to apoptosis - **cyclophosphamide**: an alkylating agent that inhibits DNA replication and transcription via cross-linking This combination, though not yet a standard regimen, has conceptual/clinical precedent in combining HER2-targeted agents, immune checkpoint inhibition, and cytotoxic chemotherapy, e.g. in locally advanced or metastatic urothelial carcinoma and breast cancer. The combination seeks to leverage synergistic anti-tumor activity across multiple mechanisms, especially in HER2-expressing tumors[1][2][3][4][5][6][7][8][9].

Other names

RC48RC-48RC 48JS001JS-001JS 001